The anti-cancer drug doxorubicin induces substantial epigenetic changes in cultured cardiomyocytes

Abstract excerpt

The anthracycline doxorubicin (DOX) is widely used in cancer therapy with the limitation of cardiotoxicity leading to the development of congestive heart failure. DOX-induced oxidative stress and changes of the phosphoproteome as well as epigenome were described but the exact mechanisms of the adverse long-term effects are still elusive. Here, we tested the impact of DOX treatment on cell death, oxidative stress...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chemotherapy-induced cardiotoxicity and mitigation
• Share to Histone Deacetylase Inhibitors Research
• Share to Sirtuins and Resveratrol in Medicine